The recent period has seen major activities for healthcare giant Johnson & Johnson. Its stock prices have been showing significant growth, with the month reporting an 11.2% surge. Notable expansion of its cancer portfolio has been made, with the $3.05 billion acquisition of Halda. However, the company's novel Alzheimer's drug failed in a key trial, causing a setback.
Employees are seeking new horizons, including the MedTech president of U.S. Orthopaedics and a few shareholders selling off their stocks. Notably, Jim Cramer has expressed fondness for J&J, and Wall Street seems increasingly bullish on the company, which recently surpassed a $500 billion market cap.
J&J's bid to launch the first icotrokinra solution for plaque psoriasis, pending FDA approval, could disrupt treatment paradigms. Discussions relating to value and valuation perspectives have been rife, given the share price momentum recently experienced. Lastly, Johnson & Johnson faces lawsuits in the UK over talcum powder cancer risks and the company has been ordered to pay $966M in a talc verdict.
Johnson Johnson JNJ News Analytics from Thu, 26 Sep 2024 07:00:00 GMT to Sat, 29 Nov 2025 18:47:50 GMT - Rating 4 - Innovation -3 - Information 6 - Rumor -5
